Veldink JH - Search Results

1

Unexpected frequency of the pathogenic AR CAG repeat expansion in the general population.

Zanovello M, Ibáñez K, Brown AL, Sivakumar P, Bombaci A, Santos L, van Vugt JJFA, Narzisi G, Karra R, Scholz SW, Ding J, Gibbs JR, Chiò A, Dalgard C, Weisburd B; American Genome Center (TAGC) consortium, Genomics England Research Consortium, Project MinE ALS Sequencing Consortium, The NYGC ALS Consortium; Hanna MG, Greensmith L, Phatnani H, Veldink JH, Traynor BJ, Polke J, Houlden H, Fratta P, Tucci A. Zanovello M, et al. Among authors: veldink jh. Brain. 2023 Jul 3;146(7):2723-2729. doi: 10.1093/brain/awad050. Brain. 2023. PMID: 36797998 Free PMC article.

2

Homozygous deletion of the survival motor neuron 2 gene is a prognostic factor in sporadic ALS.

Veldink JH, van den Berg LH, Cobben JM, Stulp RP, De Jong JM, Vogels OJ, Baas F, Wokke JH, Scheffer H. Veldink JH, et al. Neurology. 2001 Mar 27;56(6):749-52. doi: 10.1212/wnl.56.6.749. Neurology. 2001. PMID: 11274309

3

Euthanasia and physician-assisted suicide among patients with amyotrophic lateral sclerosis in the Netherlands.

Veldink JH, Wokke JH, van der Wal G, Vianney de Jong JM, van den Berg LH. Veldink JH, et al. N Engl J Med. 2002 May 23;346(21):1638-44. doi: 10.1056/NEJMsa012739. N Engl J Med. 2002. PMID: 12023997 Free article.

4

A randomized sequential trial of creatine in amyotrophic lateral sclerosis.

Groeneveld GJ, Veldink JH, van der Tweel I, Kalmijn S, Beijer C, de Visser M, Wokke JH, Franssen H, van den Berg LH. Groeneveld GJ, et al. Among authors: veldink jh. Ann Neurol. 2003 Apr;53(4):437-45. doi: 10.1002/ana.10554. Ann Neurol. 2003. PMID: 12666111 Clinical Trial.

5

Sexual differences in onset of disease and response to exercise in a transgenic model of ALS.

Veldink JH, Bär PR, Joosten EA, Otten M, Wokke JH, van den Berg LH. Veldink JH, et al. Neuromuscul Disord. 2003 Nov;13(9):737-43. doi: 10.1016/s0960-8966(03)00104-4. Neuromuscul Disord. 2003. PMID: 14561497

6

Riluzole serum concentrations in patients with ALS: associations with side effects and symptoms.

Groeneveld GJ, Van Kan HJ, Kalmijn S, Veldink JH, Guchelaar HJ, Wokke JH, Van den Berg LH. Groeneveld GJ, et al. Among authors: veldink jh. Neurology. 2003 Oct 28;61(8):1141-3. doi: 10.1212/01.wnl.0000090459.76784.49. Neurology. 2003. PMID: 14581684 Clinical Trial.

7

The future of motor neuron disease: the challenge is in the genes.

Veldink JH, Van den Berg LH, Wokke JH. Veldink JH, et al. J Neurol. 2004 Apr;251(4):491-500. doi: 10.1007/s00415-004-0322-6. J Neurol. 2004. PMID: 15083302 Review.

8

Physical activity and the association with sporadic ALS.

Veldink JH, Kalmijn S, Groeneveld GJ, Titulaer MJ, Wokke JH, van den Berg LH. Veldink JH, et al. Neurology. 2005 Jan 25;64(2):241-5. doi: 10.1212/01.WNL.0000149513.82332.5C. Neurology. 2005. PMID: 15668420 Review.

9

Few adverse effects of long-term creatine supplementation in a placebo-controlled trial.

Groeneveld GJ, Beijer C, Veldink JH, Kalmijn S, Wokke JH, van den Berg LH. Groeneveld GJ, et al. Among authors: veldink jh. Int J Sports Med. 2005 May;26(4):307-13. doi: 10.1055/s-2004-817917. Int J Sports Med. 2005. PMID: 15795816 Clinical Trial.

10

SMN genotypes producing less SMN protein increase susceptibility to and severity of sporadic ALS.

Veldink JH, Kalmijn S, Van der Hout AH, Lemmink HH, Groeneveld GJ, Lummen C, Scheffer H, Wokke JH, Van den Berg LH. Veldink JH, et al. Neurology. 2005 Sep 27;65(6):820-5. doi: 10.1212/01.wnl.0000174472.03292.dd. Epub 2005 Aug 10. Neurology. 2005. PMID: 16093455

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

347 results

Search Page